Tonbo Biosciences, a new and innovative provider of cell analysis reagents, announced today the commercial launch of its first flow cytometry product line. “The commercial launch of Tonbo’s immunophenotyping reagents signals our entry into an attractive and dynamic segment of the life sciences industry, and we’re eager to respond to a significant market need for products that are value-priced and yet meet industry standards of both quality and performance,” explained Todd R. Nelson Ph.D., CEO of Tonbo Biosciences. “Our strategy is simple—we are focused on developing a limited set of high quality, high performance flow cytometry reagents using well validated clones and standard fluorphores and we are delivering them to the market at the most competitive prices,” Nelson continued.
Robert Triulzi , Ph.D., VP of Product Development stated, “Our reagents are manufactured in our state of the art San Diego facility to the highest standards of precision and quality.” Dr. Triulzi continued, “Each of Tonbo’s products is validated for application specific performance and is optimized for use with virtually any flow cytometer.” Triulzi added, “We believe that these qualities, when presented as a part of a value-oriented reagent solution, position Tonbo as an essential partner to researchers currently coping with competing scientific and funding priorities.” Tonbo will add an additional 1,000+ immunophenotyping products during the first quarter of 2013 representing approximately 80% of the reagents used most frequently by life scientists, clinical researchers and clinicians involved in basic scientific research and drug discovery. Nelson continued, “These reagents largely target cell surface molecules such as CD3, CD4, CD8, CD19 and CD45 that provide critical insight into the immune system’s status and overall cellular function—we take great pride knowing that researchers worldwide will use our immunophenotyping products to advance their scientific discoveries.”
About Tonbo Biosciences Corporation
Founded in 2011 by an experienced team of immunologists, researchers and industry leaders, Tonbo Biosciences was conceived of a simple principle: that giving back to the research community by providing high performance, value-oriented products of the highest quality, and aligning ourselves through disciplined and innovative science with our customers, will allow us to create a unique company that is both value-oriented and technology-driven. For more information about Tonbo Biosciences Corporation, visit the company’s web site at www.tonbobio.com. Or you may email us anytime at firstname.lastname@example.org.